Showing results (131-140 of 217) with videos related to
Sort By:
Pageof 22
Journal of Palliative Medicine|March 20, 2019
Neoplastic Pericardial Effusion: A Monocentric Retrospective StudyElisabetta Di Liso, Alice Menichetti, Maria Vittoria Dieci, et al.The Oncologist|August 7, 2015
Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast CancerValentina Guarneri, Maria Vittoria Dieci, Antonio Frassoldati, et al.Neuro-Oncology|May 24, 2022
A comprehensive profiling of the immune microenvironment of breast cancer brain metastasesGaia Griguolo, Anna Tosi, Maria Vittoria Dieci, et al.Future Oncology (London, England)|December 19, 2019
Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: extending endocrine sensitivityAntonio Frassoldati, Laura Biganzoli, Roberto Bordonaro, et al.Journal of Neuro-Oncology|November 18, 2016
Beyond breast specific-Graded Prognostic Assessment in patients with brain metastases from breast cancer: treatment impact on outcomeGaia Griguolo, Maria Vittoria Dieci, Tommaso Giarratano, et al.Cancer Treatment Reviews|April 17, 2022
Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and managementSandra M Swain, Mizuki Nishino, Lisa H Lancaster, et al.European Journal of Cancer (Oxford, England : 1990)|August 26, 2019
Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trialMark Robson, Kathryn J Ruddy, Seock-Ah Im, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2005
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study groupMichel Marty, Francesco Cognetti, Dominique Maraninchi, et al.The Journal of Molecular Diagnostics : JMD|February 9, 2008
Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistryFerenc Pinter, Judit Papay, Andrea Almasi, et al.Breast Cancer Research and Treatment|November 23, 2017
Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trialJoyce O'Shaughnessy, Katarina Petrakova, Gabe S Sonke, et al.Pageof 22